This brand name is authorized in Germany, Estonia, Hong Kong, Ireland
The drug TEVANATE contains one active pharmaceutical ingredient (API):
|
1
Alendronate sodium monohydrate
UNII X1J18R4W8P - ALENDRONIC ACID
|
|
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M05BA04 | Alendronic acid | M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut fĂźr Arzneimittel und Medizinprodukte | Identifier(s): 03822671, 06325967, 06326116 |
| Country: EE | Ravimiamet | Identifier(s): 1196287, 1196300, 1196311, 1196322, 1196333, 1196344 |
| Country: HK | Department of Health Drug Office | Identifier(s): 59256 |
| Country: IE | Health Products Regulatory Authority | Identifier(s): 49413 |
Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
